Navigation Links
NeoPharm Provides Update on LE-SN38 Program

WAUKEGAN, Ill.--(BUSINESS WIRE)--Mar 30, 2007 - NEOPHARM, Inc. (Nasdaq: NEOL) today reported findings from a Phase 2 clinical trial in second-line metastatic colorectal cancer patients with its drug product candidate LE-SN38, the active metabolite of irinotecan (Camptosar(R)). While the interim analysis of data following the completion of treatment of the first 21 patients demonstrated disease stabilization, the study did not achieve the primary tumor response endpoint. No new patient accrual will be made into this study conducted by the Cancer and Leukemia Group B (CALGB), a national clinical research group sponsored by the National Cancer Institute (NCI). Patients currently receiving therapy will continue treatment per protocol until a study endpoint is reached. NeoPharm will be reassessing project next steps including additional data analyses and the possibility of other studies.

About NEOPHARM, Inc.

NEOPHARM, Inc., based in Waukegan, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. Additional information, including ongoing clinical trials, can be obtained by visiting NEOPHARM's Web site at www.neopharm.com.

Forward Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements include, but are not limited to, any statements relating to the Company's drug development program, the initiation, progress and outcomes of clin
'"/>




Page: 1 2

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. XTL Provides Update on Phase I Clinical Trial of XTL-2125
3. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
4. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NeoPharm Provides Update Program
(Date:8/19/2014)... Research and Markets has announced the addition of the ... to their offering. This report analyzes the ... following three major Application Areas: General/Abdominal Surgery, Pelvic/Gynecological Surgery, and ... analytics for the US, Canada , ... Asia-Pacific , Latin America , ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... Elbit Imaging Ltd. ("EI" or ... today that Elbit Medical Technologies Ltd. ("Elbit Medical") (TASE: ... holds approximately 86% of the voting power, announced that ... Elbit Medical holds approximately 30.8% of the voting power ... shareholders (including Elbit Medical), signed Option and Investment Agreements ...
Breaking Medicine Technology:Global Anti-Adhesion Products - Strategic Business Report 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 2Elbit Imaging Announces Gamida Cell Signs Option and Investment Agreements with Major Pharmaceutical Company 3
... to the FDA, LAUSANNE, Switzerland, November ... development specialist that,focuses on serious medical conditions ... its Canadian affiliate, filed its Complete,Response to ... States (U.S.),Food and Drug Administration (FDA) for ...
... ANTIPOLIS, France, November 4 NicOx,S.A. (Euronext Paris: ... patient Ambulatory Blood Pressure Monitoring (ABPM) trial (the ... of escalating,doses of naproxcinod and naproxen in osteoarthritis ... was the mean 24-hour,ambulatory systolic blood pressure (SBP) ...
Cached Medicine Technology:Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 2Sanvar(R) (Debio 8609) for Esophageal Variceal Bleeding 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 2NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 3NicOx Announces Favorable Blood Pressure Data for Naproxcinod in a Large ABPM Study 4
(Date:8/19/2014)... August 20, 2014 Top10BestSEOHosting.com has ... JustHost are the recommended suppliers for the webmasters ... hosting products. , According to the senior spokesman ... the most affordable hosting products on the market ... offer a variety of online deals when service ...
(Date:8/19/2014)... August 19, 2014 “ Inbox Blueprint ... course designed to provide users with the tools necessary ... marketing techniques and strategies. The course which was ... of excitement throughout the internet marketing world. The commotion ... HonestyFirstReviews.com's Tiffany Hendricks prompting an updated review of the ...
(Date:8/19/2014)... August 19, 2014 Horizon Blue Cross Blue ... Morgan Hoffmann are once again teaming up during The ... cause through a Walking Challenge, and Horizon BCBSNJ will be ... a course challenge of their own. , Horizon BCBSNJ, the ... is making a $5,000 donation to the New Jersey Golf ...
(Date:8/19/2014)... (HealthDay News) -- Lupus and other rheumatic diseases ... seizures, which can delay a correct diagnosis for ... rheumatic diseases can also cause these types of ... Center in Maywood, Ill. Rheumatic disorders include ... soft tissues, such as lupus, systemic vasculitis and ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
Breaking Medicine News(10 mins):Health News:Fatcow Awarded As One of the Best Web Hosting Suppliers at Top10bestseohosting.com 2Health News:Anik Singal’s “Inbox Blueprint” Review Released By HonestyFirstReviews.com 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 2Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 3Health News:Horizon Blue Cross Blue Shield of New Jersey Pairs up with PGA TOUR Pro Morgan Hoffmann for Walking Challenge During The Barclays for Charity and to Promote Good Health 4Health News:Certain Symptoms Can Delay Lupus Diagnosis, Researchers Report 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3
... today that it has dosed its first patient in ... ALT-2074, its lead glutathione peroxidase mimetic, in diabetic ... at high risk for cardiovascular complications. , ... ability to lower inflammatory cardiovascular biomarkers in patients with ...
... (JCVI) today announced the results of work on genome ... bacteria into another type dictated by the transplanted chromosome. ... journal Science, by JCVI's Carole Lartigue, Ph.D. and colleagues, ... bacterial species, Mycoplasma capricolum into another, Mycoplasma mycoides Large ...
... Businesses that offer customers shisha water pipes to smoke tobacco ... smoking ban that comes into force in England on Sunday. ... the water pipes are variously called, dozens of restaurants will ... see their sole activity disappear. ,"It's a disaster, ...
... name, one might rhetorically ask. But Malaccan state authorities have ... after their region. And now the virus will carry some ... announced last week they discovered a new virus likely carried ... called it the Melaka Virus, using the name of the ...
... with most other developing countries, plastic bags have become a terrible ... to be spiraling out of control, the government has announced a ... Uganda they are called buveera , and they are everywhere. ... organized dump like the one at Chitezi in Ugandan capital Kampala. ...
... found that nonsmoking restaurant and bar employees absorb a ... in places where they had to breathe tobacco smoke ... in the body only as a result of using ... the Multnomah County Health Department and Oregon Department of ...
Cached Medicine News:Health News:Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2 2Health News:First Bacterial Genome Transplantation Changing One Species to Another 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 2Health News:Shisha Owners Mobilise Against July 1 Smoking Ban in England 3Health News:Mealaka Virus Will Have a New Name 2Health News:Uganda Bans Plastic Bags, Still a Tough Battle Lies Ahead 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 2Health News:Non Smoking Workers Absorb the Carcinogen Immediately 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: